CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
Byung Chul You, Young Seok Kim, Hun il Kim, Se Hun Kim, Seung Sik Park, Yu Ri Seo, Sang Gyune Kim, Se Whan Lee, Hong Soo Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
Clin Mol Hepatol. 2012;18(3):272-278.   Published online 2012 September 25    DOI: https://doi.org/10.3350/cmh.2012.18.3.272

Excel Download

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
Clinical and Molecular Hepatology. 2012;18(3):272   Crossref logo
Link1 Link2

Pegylated interferon alpha 2B (peg IFN)_plus ribavirin (R) for the treatment of chronic hepatitis c: optimization fo ribavirin dose
Journal of Hepatology. 2001;34:237-257   Crossref logo
Link1 Link2

Combination treatment of alpha interferon-2b (alpha IFN) and ribavirin in chronic hrpatitis C genotype 4 patients resistant to interferon therapy
Hepatology. 1995;22(4):A152   Crossref logo
Link1 Link2

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with theIL28Bminor genotype
Journal of Gastroenterology and Hepatology. 2013;28(3):443-449   Crossref logo
Link1

PP-131 Biochemical Response with interferon alpha 2b and ribavirin combination therapy in chronic hepatitis C patients
International Journal of Infectious Diseases. 2009;13:S84   Crossref logo
Link1 Link2

Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy)
Gastroenterology. 2001;120(5):A568   Crossref logo
Link1 Link2

Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy)
Gastroenterology. 2001;120(5):A568-A568   Crossref logo
Link1 Link2

Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b
Hepatology Research. 2009;39(6):539-545   Crossref logo
Link1

457 Retreatment with pegylated interferon alpha-2B and ribavirin in patients with chronic hepatitis C non responders to interferon monotherapy or interferon and ribavirin combination. A prospective randomized pilote study of two regimens: Induction versus REG
Journal of Hepatology. 2004;40:135   Crossref logo
Link1 Link2

PEG-interfeoon α-2b + ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon alfa or interferon a-2b + ribavirin therapy
Gastroenterology. 2003;124(4):A783   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.